RNA-cap
Loading...Anti-RNA-cap Products
+ Filter
Loading...- Recombinant Anti-RNA-cap Antibody (MOB-858)
-
- Derivation: Mouse
- Type: IgG
- Application: WB, Dot, FuncS
Compare
- Recombinant Human Anti-RNA-cap Antibody (MHH-858)
-
- Derivation: Human
- Type: IgG
- Application: ELISA, WB, FuncS
Compare
- Recombinant Human Anti-RNA-cap Antibody Fab Fragment (MHH-858-F(E))
-
- Derivation: Human
- Type: Fab
- Application: ELISA, WB, FuncS
Compare
- Recombinant Human Anti-RNA-cap Antibody scFv Fragment (MHH-858-S(P))
-
- Derivation: Human
- Type: scFv
- Application: ELISA, IP, FuncS
Compare
- Recombinant Anti-RNA-cap Antibody Fab Fragment (MOB-858-F(E))
-
- Derivation: Mouse
- Type: Fab
- Application: ELISA, FacS, FuncS
Compare
- Recombinant Anti-RNA-cap Antibody scFv Fragment (MOB-858-S(P))
-
- Derivation: Mouse
- Type: scFv
- Application: ELISA, WB, IF, FuncS
Compare
View More Products
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
More Infomation
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Background
The 5' terminal m7G cap present on most eukaryotic mRNAs promotes translation, in vitro, at the initiation level. For most RNAs, the cap structure increases stability, decreases susceptibility to exonuclease degradation, and promotes the formation of mRNA initiation complexes. Certain prokaryotic mRNAs with 5' terminal cap structures are translated as efficiently as eukaryotic mRNAs in a eukaryotic cell-free protein synthesizing system. Splicing of certain eukaryotic substrate RNAs has also been observed to require a cap structure